180 related articles for article (PubMed ID: 9557608)
1. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers.
Pilarski LM; Yatscoff RW; Murphy GF; Belch AR
Leukemia; 1998 Apr; 12(4):505-9. PubMed ID: 9557608
[TBL] [Abstract][Full Text] [Related]
2. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
3. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma.
Pilarski LM; Szczepek AJ; Belch AR
Blood; 1997 Nov; 90(9):3751-9. PubMed ID: 9345062
[TBL] [Abstract][Full Text] [Related]
4. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
Zacherl J; Hamilton G; Thalhammer T; Riegler M; Cosentini EP; Ellinger A; Bischof G; Schweitzer M; Teleky B; Koperna T
Cancer Chemother Pharmacol; 1994; 34(2):125-32. PubMed ID: 7910786
[TBL] [Abstract][Full Text] [Related]
6. Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology.
Silverman JA; Hayes ML; Luft BJ; Joiner KA
Antimicrob Agents Chemother; 1997 Sep; 41(9):1859-66. PubMed ID: 9303374
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.
Loor F; Tiberghien F; Wenandy T; Didier A; Traber R
J Med Chem; 2002 Oct; 45(21):4598-612. PubMed ID: 12361387
[TBL] [Abstract][Full Text] [Related]
8. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma.
Pilarski LM; Belch AR
Blood; 1994 Feb; 83(3):724-36. PubMed ID: 7507731
[TBL] [Abstract][Full Text] [Related]
9. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.
Uchiyama-Kokubu N; Watanabe T; Cohen D
Jpn J Cancer Res; 2001 Oct; 92(10):1116-26. PubMed ID: 11676863
[TBL] [Abstract][Full Text] [Related]
10. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes.
Yacyshyn BR; Bowen-Yacyshyn MB; Pilarski LM
Scand J Immunol; 1996 Apr; 43(4):449-55. PubMed ID: 8668925
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites.
Demeule M; Laplante A; Sepehr-Araé A; Beaulieu E; Averill-Bates D; Wenger RM; Béliveau R
Biochem Cell Biol; 1999; 77(1):47-58. PubMed ID: 10426286
[TBL] [Abstract][Full Text] [Related]
12. The potent immunosuppressive cyclosporin FR901459 inhibits the human P-glycoprotein and formyl peptide receptor functions.
Tiberghien F; Wenandy T; Loor F
J Antibiot (Tokyo); 2000 May; 53(5):509-15. PubMed ID: 10908115
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of cyclosporin G (OG37-325), cyclosporin A, and their metabolites on the release of endothelin and prostacyclin from primary renal and aortic endothelial cell lines.
Langman LJ; Yatscoff RW
Ther Drug Monit; 1994 Oct; 16(5):450-7. PubMed ID: 7846742
[TBL] [Abstract][Full Text] [Related]
14. A bioassay for the activity of PSC 833 in human serum for modulation of P-glycoprotein-mediated multidrug resistance.
Uchiyama-Kokubu N; Watanabe T; Nakajima M
Anticancer Drugs; 2000 Aug; 11(7):583-90. PubMed ID: 11036963
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro.
Haberl I; Swatonek H; Schaufler K; Ulsperger E; Wenzl E; Theyer G; Hamilton G; Thalhammer T
Int J Oncol; 1998 May; 12(5):1137-42. PubMed ID: 9538140
[TBL] [Abstract][Full Text] [Related]
16. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
17. Transport activity and surface expression of the Na+-Ca2+ exchanger NCX1 are inhibited by the immunosuppressive agent cyclosporin A and by the nonimmunosuppressive agent PSC833.
Kimchi-Sarfaty C; Kasir J; Ambudkar SV; Rahamimoff H
J Biol Chem; 2002 Jan; 277(4):2505-10. PubMed ID: 11700317
[TBL] [Abstract][Full Text] [Related]
18. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment.
Jetté L; Murphy GF; Béliveau R
Int J Cancer; 1998 May; 76(5):729-37. PubMed ID: 9610733
[TBL] [Abstract][Full Text] [Related]
19. Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.
Dietel M; Herzig I; Reymann A; Brandt I; Schaefer B; Bunge A; Heidebrecht HJ; Seidel A
J Cancer Res Clin Oncol; 1994; 120(5):263-71. PubMed ID: 7907333
[TBL] [Abstract][Full Text] [Related]
20. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.
Merlin JL; Guerci AP; Marchal S; Bour C; Colosetti P; Kataki A; Guerci O
Br J Haematol; 1998 Nov; 103(2):480-7. PubMed ID: 9827923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
